Fig. 3.

Post-BBBO cfDNA has distinctive disease-specific signature. (A) Principal component analysis shows a separation of the methylation signature of pre- and post-BBBO cfDNA. (B) Results of a functional enrichment analysis of the differentially hypomethylated probe set based on the Human Protein Atlas. (C) Results of a principal component analysis of methylation data with cfDNA from non-brain tumor patients’ post-BBBO as controls suggest disease-specific signatures. Abbreviations: BBBO, BBB opening, cfDNA, cell-free DNA; GBM, glioblastoma.